argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 402.79 Million EUR | 25.65% |
| 2022 | 320.56 Million USD | 1.43% |
| 2021 | 316.05 Million USD | -47.91% |
| 2020 | 606.75 Million EUR | 41.58% |
| 2019 | 428.56 Million EUR | 835.17% |
| 2018 | 45.82 Million EUR | 47.05% |
| 2017 | 31.16 Million EUR | -30.11% |
| 2016 | 44.59 Million EUR | 369.65% |
| 2015 | 9.49 Million EUR | -7.36% |
| 2014 | 10.24 Million EUR | 124.36% |
| 2013 | 4.56 Million EUR | -27.24% |
| 2012 | 6.27 Million EUR | 55.3% |
| 2011 | 4.04 Million EUR | 99.25% |
| 2010 | 2.02 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | 534.31 Million EUR | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 335.74 Million USD | 0.0% |
| 2023 FY | 402.79 Million EUR | 25.65% |
| 2023 Q4 | 444.95 Million USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 FY | 320.56 Million USD | 1.43% |
| 2022 Q2 | 279.01 Million USD | 0.0% |
| 2022 Q4 | 320.56 Million USD | 0.0% |
| 2021 Q4 | 316.05 Million USD | 0.0% |
| 2021 FY | 316.05 Million USD | -47.91% |
| 2021 Q2 | 261.08 Million USD | 0.0% |
| 2020 Q4 | 606.75 Million EUR | 0.0% |
| 2020 Q2 | 456.61 Million EUR | 0.0% |
| 2020 FY | 606.75 Million EUR | 41.58% |
| 2019 FY | 428.56 Million EUR | 835.17% |
| 2019 Q2 | 390.84 Million EUR | 0.0% |
| 2019 Q4 | 382.59 Million EUR | 0.0% |
| 2018 Q2 | 31.28 Million EUR | 0.0% |
| 2018 FY | 45.82 Million EUR | 47.05% |
| 2018 Q4 | 45.82 Million EUR | 0.0% |
| 2017 FY | 31.16 Million EUR | -30.11% |
| 2017 Q4 | 31.16 Million EUR | 0.0% |
| 2017 Q2 | 40.3 Million EUR | 0.0% |
| 2016 Q2 | 46.64 Million EUR | 0.0% |
| 2016 Q4 | 44.59 Million EUR | 0.0% |
| 2016 FY | 44.59 Million EUR | 369.65% |
| 2015 FY | 9.49 Million EUR | -7.36% |
| 2015 Q2 | 11.59 Million EUR | 0.0% |
| 2015 Q4 | 9.49 Million EUR | 0.0% |
| 2014 Q1 | 3.66 Million EUR | -19.7% |
| 2014 Q4 | 10.24 Million EUR | 0.0% |
| 2014 Q2 | 14.12 Million EUR | 285.0% |
| 2014 FY | 10.24 Million EUR | 124.36% |
| 2013 Q4 | 4.56 Million EUR | 0.0% |
| 2013 FY | 4.56 Million EUR | -27.24% |
| 2012 FY | 6.27 Million EUR | 55.3% |
| 2011 FY | 4.04 Million EUR | 99.25% |
| 2010 FY | 2.02 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -5727.52% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -207.358% |
| Adocia SA | 31.87 Million EUR | -1163.879% |
| Aelis Farma SA | 13.08 Million EUR | -2979.497% |
| Biophytis S.A. | 15.84 Million EUR | -2441.474% |
| Advicenne S.A. | 24.37 Million EUR | -1552.37% |
| genOway Société anonyme | 14.45 Million EUR | -2685.697% |
| IntegraGen SA | 5.97 Million EUR | -6635.984% |
| Medesis Pharma S.A. | 6.42 Million EUR | -6168.077% |
| Neovacs S.A. | 3.71 Million EUR | -10750.881% |
| NFL Biosciences SA | 3.62 Million EUR | -11024.922% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -5838.916% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -12068.736% |
| Sensorion SA | 13.22 Million EUR | -2945.21% |
| Theranexus Société Anonyme | 5.01 Million EUR | -7929.964% |
| TME Pharma N.V. | 2.78 Million EUR | -14363.13% |
| Valbiotis SA | 13.7 Million EUR | -2838.417% |
| TheraVet SA | 1.48 Million EUR | -27024.584% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -1867.941% |
| BioSenic S.A. | 32.26 Million EUR | -1148.445% |
| Celyad Oncology SA | 9.97 Million EUR | -3936.863% |
| DBV Technologies S.A. | 38.74 Million USD | -939.605% |
| Galapagos NV | 1.56 Billion EUR | 74.21% |
| Genfit S.A. | 105.92 Million EUR | -280.282% |
| GeNeuro SA | 20.13 Million EUR | -1900.001% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -4577.173% |
| Innate Pharma S.A. | 132.29 Million EUR | -204.477% |
| Inventiva S.A. | 101.59 Million EUR | -296.482% |
| MaaT Pharma SA | 22.46 Million EUR | -1693.003% |
| MedinCell S.A. | 77.77 Million EUR | -417.935% |
| Nanobiotix S.A. | 95.74 Million EUR | -320.721% |
| Onward Medical N.V. | 25.69 Million EUR | -1467.43% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -1503.145% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -581.796% |
| Oxurion NV | 19.73 Million EUR | -1940.931% |
| Pharming Group N.V. | 228.28 Million EUR | -76.445% |
| Poxel S.A. | 53.9 Million EUR | -647.293% |
| GenSight Biologics S.A. | 34.72 Million EUR | -1059.899% |
| Transgene SA | 26.51 Million EUR | -1419.019% |
| Financière de Tubize SA | 123.65 Million EUR | -225.756% |
| UCB SA | 6.56 Billion EUR | 93.864% |
| Valneva SE | 341.14 Million EUR | -18.073% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -8758.548% |